{"id":"dapagliflozin-metformin-pill","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Genital mycotic infections"},{"rate":"3-8","effect":"Urinary tract infections"},{"rate":"10-15","effect":"Gastrointestinal disturbances (nausea, diarrhea)"},{"rate":"1-5","effect":"Hypoglycemia"},{"rate":"2-5","effect":"Volume depletion / orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dapagliflozin is an SGLT2 inhibitor that blocks reabsorption of glucose in the proximal tubule, promoting glucose excretion in urine and lowering blood glucose independently of insulin. Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. Together, they provide complementary glucose-lowering effects through distinct mechanisms.","oneSentence":"Dapagliflozin inhibits SGLT2 to increase urinary glucose excretion, while metformin reduces hepatic glucose production and improves insulin sensitivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:10.103Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06000462","phase":"PHASE4","title":"The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oman Ministry of Health","startDate":"2024-04-22","conditions":"Obesity, Dapagliflozin Adverse Reaction, Weight Loss","enrollment":150},{"nctId":"NCT05440591","phase":"PHASE4","title":"Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes","status":"UNKNOWN","sponsor":"Tan Tock Seng Hospital","startDate":"2019-04-01","conditions":"Diabetes","enrollment":150},{"nctId":"NCT02235298","phase":"PHASE4","title":"Dapagliflozin Effects on Epicardial Fat","status":"COMPLETED","sponsor":"University of Miami","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT02635386","phase":"PHASE3","title":"EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Woman's","startDate":"2016-03-22","conditions":"Polycystic Ovary Syndrome, Obesity","enrollment":119},{"nctId":"NCT04195243","phase":"PHASE3","title":"Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Centro Universitario de Ciencias de la Salud, Mexico","startDate":"2019-12-02","conditions":"Type 2 Diabetes Mellitus","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dapagliflozin / metFORMIN Pill","genericName":"Dapagliflozin / metFORMIN Pill","companyName":"Tan Tock Seng Hospital","companyId":"tan-tock-seng-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dapagliflozin inhibits SGLT2 to increase urinary glucose excretion, while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}